Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

E. H. Corder; A. M. Saunders; N. J. Risch; W. J. Strittmatter; D. E. Schmechel; P. C. Gaskell; J. B. Rimmler; P. A. Locke; P. M. Conneally; K. E. Schmader; G. W. Small; A. D. Roses; J. L. Haines; M. A. Pericak-Vance

doi:10.1038/ng0694-180

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

E. H. Corder, A. M. Saunders, N. J. Risch, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, J. B. Rimmler, P. A. Locke, P. M. Conneally, K. E. Schmader, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance

Research output: Contribution to journal › Article

1330 Scopus citations

Abstract

Gene dosage of the apolipoprotein E (APOE) ε4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the ε2 allele, in addition to the dose effect of the ε4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of ε4 alleles, risk of AD is lowest in subjects with the ε2/ε3 genotype, with an additional 23% of AD attributable to the absence of an ε2 allele. The opposite actions of the ε2 and ε4 alleles further support the direct involvement of APOE in the pathogenesis of AD.

Original language	English (US)
Pages (from-to)	180-184
Number of pages	5
Journal	Nature genetics
Volume	7
Issue number	2
DOIs	https://doi.org/10.1038/ng0694-180
State	Published - Jun 1 1994
Externally published	Yes

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/ng0694-180

Fingerprint Dive into the research topics of 'Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease'. Together they form a unique fingerprint.

Cite this

Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature genetics, 7(2), 180-184. https://doi.org/10.1038/ng0694-180

Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. / Corder, E. H.; Saunders, A. M.; Risch, N. J.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Rimmler, J. B.; Locke, P. A.; Conneally, P. M.; Schmader, K. E.; Small, G. W.; Roses, A. D.; Haines, J. L.; Pericak-Vance, M. A.

In: Nature genetics, Vol. 7, No. 2, 01.06.1994, p. 180-184.

Research output: Contribution to journal › Article

Corder, E. H. ; Saunders, A. M. ; Risch, N. J. ; Strittmatter, W. J. ; Schmechel, D. E. ; Gaskell, P. C. ; Rimmler, J. B. ; Locke, P. A. ; Conneally, P. M. ; Schmader, K. E. ; Small, G. W. ; Roses, A. D. ; Haines, J. L. ; Pericak-Vance, M. A. / Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. In: Nature genetics. 1994 ; Vol. 7, No. 2. pp. 180-184.

@article{353d41138adc4aec8cd2bfeb79f88b23,

title = "Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease",

abstract = "Gene dosage of the apolipoprotein E (APOE) ε4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the ε2 allele, in addition to the dose effect of the ε4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of ε4 alleles, risk of AD is lowest in subjects with the ε2/ε3 genotype, with an additional 23% of AD attributable to the absence of an ε2 allele. The opposite actions of the ε2 and ε4 alleles further support the direct involvement of APOE in the pathogenesis of AD.",

author = "Corder, {E. H.} and Saunders, {A. M.} and Risch, {N. J.} and Strittmatter, {W. J.} and Schmechel, {D. E.} and Gaskell, {P. C.} and Rimmler, {J. B.} and Locke, {P. A.} and Conneally, {P. M.} and Schmader, {K. E.} and Small, {G. W.} and Roses, {A. D.} and Haines, {J. L.} and Pericak-Vance, {M. A.}",

year = "1994",

month = jun,

day = "1",

doi = "10.1038/ng0694-180",

language = "English (US)",

volume = "7",

pages = "180--184",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

AU - Corder, E. H.

AU - Saunders, A. M.

AU - Risch, N. J.

AU - Strittmatter, W. J.

AU - Schmechel, D. E.

AU - Gaskell, P. C.

AU - Rimmler, J. B.

AU - Locke, P. A.

AU - Conneally, P. M.

AU - Schmader, K. E.

AU - Small, G. W.

AU - Roses, A. D.

AU - Haines, J. L.

AU - Pericak-Vance, M. A.

PY - 1994/6/1

Y1 - 1994/6/1

N2 - Gene dosage of the apolipoprotein E (APOE) ε4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the ε2 allele, in addition to the dose effect of the ε4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of ε4 alleles, risk of AD is lowest in subjects with the ε2/ε3 genotype, with an additional 23% of AD attributable to the absence of an ε2 allele. The opposite actions of the ε2 and ε4 alleles further support the direct involvement of APOE in the pathogenesis of AD.

AB - Gene dosage of the apolipoprotein E (APOE) ε4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the ε2 allele, in addition to the dose effect of the ε4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of ε4 alleles, risk of AD is lowest in subjects with the ε2/ε3 genotype, with an additional 23% of AD attributable to the absence of an ε2 allele. The opposite actions of the ε2 and ε4 alleles further support the direct involvement of APOE in the pathogenesis of AD.

UR - http://www.scopus.com/inward/record.url?scp=0028305380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028305380&partnerID=8YFLogxK

U2 - 10.1038/ng0694-180

DO - 10.1038/ng0694-180

M3 - Article

C2 - 7920638

AN - SCOPUS:0028305380

VL - 7

SP - 180

EP - 184

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 2

ER -